The original drug, GSK Avodart, was the first in 2021 to go beyond Propecia (Finasteride), leading to the market for two consecutive years until last year. In the case of generic, Dutasteride grows steeply and pursues the Finesteride quickly. In the pharmaceutical industry, the new formulation product is cited as a variable in the market. Boryeong's newly -made FINASTERIDE ingredient has been released, and Chong Kun Dang is developing a product of an injection formulation.

◆ Avodart's sales last year sales of 43.6 billion won VS Propecia's sales of 39.6 billion won

According to IQVIA, a pharmaceutical market research firm on the 15th, GSK Avodart's sales last year were 43.6 billio